American Century Companies Inc. Boosts Position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

American Century Companies Inc. raised its stake in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) by 49.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 30,315 shares of the company’s stock after purchasing an additional 9,984 shares during the period. American Century Companies Inc. owned 0.11% of Vistagen Therapeutics worth $105,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of VTGN. ADAR1 Capital Management LLC purchased a new stake in shares of Vistagen Therapeutics in the fourth quarter worth about $1,262,000. BVF Inc. IL bought a new position in shares of Vistagen Therapeutics in the 4th quarter worth $10,280,000. Great Point Partners LLC purchased a new stake in Vistagen Therapeutics during the fourth quarter valued at approximately $9,554,000. Acadian Asset Management LLC acquired a new stake in Vistagen Therapeutics in the first quarter worth about $169,000. Finally, StemPoint Capital LP raised its holdings in shares of Vistagen Therapeutics by 3.3% in the first quarter. StemPoint Capital LP now owns 1,848,582 shares of the company’s stock worth $9,292,000 after buying an additional 58,400 shares during the last quarter. 78.39% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, William Blair raised Vistagen Therapeutics to a “strong-buy” rating in a report on Friday, August 30th.

Vistagen Therapeutics Trading Up 2.0 %

Shares of NASDAQ VTGN opened at $3.01 on Friday. The company has a 50-day moving average of $3.29 and a 200 day moving average of $3.87. The stock has a market cap of $81.35 million, a PE ratio of -1.45 and a beta of 0.78. Vistagen Therapeutics, Inc. has a 12-month low of $2.45 and a 12-month high of $5.86.

Vistagen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.06. The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.30 million. Vistagen Therapeutics had a negative net margin of 3,421.85% and a negative return on equity of 35.12%. During the same quarter in the previous year, the company earned ($0.94) EPS. On average, sell-side analysts forecast that Vistagen Therapeutics, Inc. will post -1.79 EPS for the current fiscal year.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.